MISSION STATEMENT: Qualyst’s mission is to develop and deliver novel and proprietary ADMET products to the life sciences industry that increase the efficiency and effectiveness of drug discovery and development.

TYPE OF COMPANY: biotechnology

ADDRESS: 7030 Kit Creek Road, PO Box 12199, RTP, NC 27709

PHONE NUMBER: 919.313.6500

WEB SITE: www.qualyst.com

MANAGEMENT TEAM MEMBERS (include a brief background about each executive, with their title):
Scott E. Neuville, President and CEO, Neuville is the former Chairman of the Board and Chief Executive Officer of iBiomatics, a SAS company. iBiomatics was the first healthcare technology spin-off of SAS Institute, the worlds largest privately held software company. Prior to iBiomatics, a SAS company, Neuville served as an executive with a health care software company. He played a role in the development of the company that led to a merger with A4 Healthsystems in 2000. Prior to the year 2000, Neuville spent seven years at STERIS Corporation (NYSE:STE) in several senior executive roles including President of the Americas Healthcare Division. Neuville played a key leadership role in the rapid growth of the company from $12 million in annual sales to more than $800 million at the time of his departure. During his executive tenure, STERIS was recognized as one of the fastest growing healthcare companies of the 90’s and as the ninth-fastest growing publicly held company in the United States.

Kenneth R. Brouwer, Ph.D., RPh., Vice President of Research and Development, Dr. Brouwer has over 18 years of experience in the pharmaceutical industry. Most recently, Dr. Brouwer served as Executive Director, Drug Metabolism and Pharmacokinetics, at PPD Discovery, USA, where he had complete responsibility for overseeing the scientific and administrative operations within the preclinical groups at PPD Discovery, including ADMET. Prior to PPD, he served as Director, Preclinical Development, Drug Metabolism and Pharmacokinetics at GlaxoSmithKline and was responsible for the drug metabolism and pharmacokinetics strategy leading to candidate selection.

Marc Sedam, MBA, Vice President for Corporate Development, Mr. Sedam has more than a decade of experience in intellectual property management and product development, including negotiating over 60 license agreements. At Qualyst, he is responsible for intellectual property management, and product licensing. Most recently, Mr. Sedam spent eight years at The University of North Carolina at Chapel Hill’s technology transfer office as Associate Director, focusing specifically in the areas of pharmaceuticals and biotechnology.

Ian J. Mehr, Ph.D., MBA, Senior Director, Business Development , Dr. Mehr has more than a decade of experience in the life science industry, spanning both research and business development. Dr. Mehr’s previous corporate experience includes the positions of Director of Business Development at Paradigm Genetics, Inc, and Strategic Business Director at Laboratory Corporation of America.

Robert L. St. Claire III, Ph.D., Director of Chemistry, Dr. St. Claire has 19 years of experience in the fields of bioanalytical and analytical chemistry within the pharmaceutical industry. As a senior technical leader at Glaxo, Glaxo Wellcome, Triangle Pharmaceuticals, and most recently at Gilead Sciences, his primary focus has been in novel technology development, methods development, and teaching. His most notable accomplishments have been in the development of technology analyzing intracellular metabolism. His work in Dr. Jim Jorgenson’s lab at UNC-Chapel Hill produced the first liquid chromatography microcolumns used in the analysis of the chemical composition within a single cell.

Scott Neuville (President and CEO, Qualyst)
Dhiren R. Thakker, Ph.D., (Qualyst Co-Founder & Professor, The University of North Carolina at Chapel Hill )
Ronald T. Borchardt, Ph.D. (Professor, The University of Kansas)

Harold Lichtin (CEO, The Lichtin Corporation)

INVESTORS (and amounts raised, if possible):
Burton Advisors Ltd. served as our primary placement agent…US$2.75m Series A financing

REVENUES: The Company has generated revenue in 2003 and 2004 and projects greater than two million dollars in revenue for 2005. The company projects to be cash flow positive from operations by the end of 2005.

YEAR ESTABLISHED: 2001, laboratory operations commenced in 2003